← All trials
NCT04361474
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 18, 2020
- Primary completion
- May 18, 2020
- Completion date
- May 25, 2021
- First posted
- Apr 24, 2020
- Last posted
- May 20, 2020
- Enrollment
- 120
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Adolphe Rothschild Ophtalmologic FoundationLead sponsor
- University of ParisCollaborator
- Adolphe Rothschild Ophtalmologic FoundationOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.